Functional and structural analysis of influenza virus neuraminidase N3 offers further insight into the mechanisms of oseltamivir resistance

Journal of Virology

Volumn 87, Issue 18, 2013, Pages 10016-10024

  Li, Qing ^a,b   Qi, Jianxun ^b   Wu, Yan ^b   Kiyota, Hiromasa ^c   Tanaka, Kosuke ^c   Suhara, Yoshitomo ^d   Ohrui, Hiroshi ^e   Suzuki, Yasuo ^f   Vavricka, Christopher J ^b,g   Gao, George F ^a,b,g  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c TOHOKU UNIVERSITY   (Japan)

^d SHIBAURA INSTITUTE OF TECHNOLOGY   (Japan)

^e YOKOHAMA COLLEGE OF PHARMACY   (Japan)

^f CHUBU UNIVERSITY   (Japan)

^g INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; GLUTAMINE; HISTIDINE; LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; PHENYLALANINE; PROLINE; SERINE; THREONINE; TYROSINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; VIRUS SIALIDASE N1; VIRUS SIALIDASE N3; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; INFLUENZA VIRUS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; PROTEIN CONFORMATION; VIRAL PROTEINS;

EID: 84883282363     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01129-13     Document Type: Article

References (37)

1. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Suzuki H, Nishimura H, Mitamura K, Sugaya N, Usui T, Murata T,Maeda Y, Watanabe S, Suresh M, Suzuki T, Suzuki Y, Feldmann H, Kawaoka Y. 2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-707.
2. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, Basler CF. 2004. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. U. S. A. 101:3166-3171.
3. Suzuki Y, Ito T, Suzuki T, Holland RE, Chambers TM, Kiso M, Ishida H, Kawaoka Y. 2000. Sialic acid species as a determinant of the host range of influenza A viruses. J. Virol. 74:11825-11831.
4. Ma W, Lager KM, Vincent AL, Janke BH, Gramer MR, Richt JA. 2009. The role of swine in the generation of novel influenza viruses. Zoonoses Public Health 56:326-337.
5. Scholtissek C, Burger H, Kistner O, Shortridge KF. 1985. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. Virology 147:287-294.
6. Ma W, Vincent AL, Gramer MR, Brockwell CB, Lager KM, Janke BH, Gauger PC, Patnayak DP, Webby RJ, Richt JA. 2007. Identification of H2N3 influenza A viruses from swine in the United States. Proc. Natl. Acad. Sci. U. S. A. 104:20949-20954.
7. Vavricka CJ, Liu Y, Li Q, Shi Y, Wu Y, Sun Y, Qi J, Gao GF. 2011. Special features of the 2009 pandemic swine-origin influenza A H1N1 hemagglutinin and neuraminidase. Chin. Sci. Bull. 56:1747-1752.
8. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen L, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. 2012. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. U. S. A. 109:4269-4274.
9. Li Q, Sun X, Li Z, Liu Y, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. 2012. Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 109:18897-18902.
10. Zhu X, Yang H, Guo Z, Yu W, Carney PJ, Li Y, Chen LM, Paulson JC, Donis RO, Tong S, Stevens J, Wilson IA. 2012. Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Proc. Natl. Acad. Sci. U. S. A. 109: 18903-18908.
11. Wang M, Qi J, Liu Y, Vavricka CJ, Wu Y, Li Q, Gao GF. 2011. Influenza A virus neuraminidase N5 has an extended 150-cavity. J. Virol. 85:8431-8435.
12. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
13. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent antiinfluenza activity. J. Am. Chem. Soc. 119:681-690.
14. Sidwell RW, Smee DF. 2002. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin. Invest. Drugs 11:859-869.
15. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubu S. 2009. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 53:186-192.
16. Vavricka CJ, Qi J, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF. 2011. Structural and functional analysis of laninamivir and its octanoateprodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 7:e1002249. doi: 10.1371/journal.ppat.1002249.
17. Li Q, Feng E, Liu H, Gao GF. 2010. The design and development of influenza virus neuraminidase inhibitors on the basis of crystal structures. Biotech. Bus. 6:42-48. (In Chinese.)
18. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M, WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals. 2012. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12: 240-248.
19. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM. 1998. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735-746.
20. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Martin SR, Daniels RS, Gregory V, Skehel JJ, Gamblin SJ, Hay AJ. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:6317-6323.
21. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gambling SJ. 2008. Crystal structures of oseltamivirresistant influenza virus neuraminidase mutants. Nature 453:1258-1261.
22. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
23. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13(5):Article 2. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8026.
24. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103. doi:10.1371/journal.ppat.1000103.
25. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-DN-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
26. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Method. Enzymol. 276:307-326.
27. Read RJ. 2001. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr.DBiol. Crystallogr. 57:1373-1382.
28. Collaborative Computational Project Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
29. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240-255.
30. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
31. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive pythonbased system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221.
32. Laskowski RA, Macarthur MW, Moss DS, Thornton JM. 1993. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283-291.
33. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. 2008. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 82: 10493-10501.
34. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. 2010. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 17:1266-1268.
35. Vavricka CJ, Liu Y, Kiyota H, Sriwilaijaroen N, Qi J, Tanaka K, Wu Y, Li Q., Li Y, Yan J, Suzuki Y, Gao GF. 2013 Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Nat. Commun. 2013:e2487. doi:10.1038/ncomms2487.
36. Watts AG, Oppezzo P, Withers SG, Alzari PM, Buschiazzo A. 2006. Structural and kinetic analysis of two covalent sialosyl-enzyme intermediates on trypanosomarangelisialidase. J. Biol. Chem. 281:4149-4155.
37. Newstead SL, Potter JA, Wilson JC, Xu G, Chien CH, Watts AG, Withers SG, Taylor GL. 2008. The structure of Clostridium perfringens NanI sialidase and its catalytic intermediates. J. Biol. Chem. 283:9080-9088.